Comment on "A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder"'

CNS Drugs. 2025 Jan 2. doi: 10.1007/s40263-024-01152-6. Online ahead of print.
No abstract available

Publication types

  • Letter
  • Comment